PCN66 A Cost and Outcomes Analysis of Bevacizumab plus Folfiri Versus Cetuximab Plus Folfiri for the Treatment of First-Line Metastatic Colorrectal Cancer Patients from the Brazilian Private Payer Perspective
Abstract
Authors
R. Caponero E.A.V. Santos C.T. Buschinelli M. Ferracini C.A. Ngoh